Cancer

Mouse studies suggest combining the c-MET inhibitor capmatinib with immunotherapies could help treat melanoma, breast and colorectal cancers. In mouse models of c-MET-dependent and -independent melanoma, adoptive transfer of melanoma antigen-targeting T cells, the generic chemotherapy cyclophosphamide and the c-Met inhibitor capmatinib increased survival compared with adoptive T cell transfer of immunotherapy plus cyclophosphamide. In mouse models of melanoma, the combination of an anti-PD-1 antibody, the innate immune activators CpG and poly(I:C) and capmatinib increased survival compared with the anti-PD-1 antibody plus immune activators. In mouse models of colon and breast cancer, the anti-PD-1 antibody plus capmatinib increased survival compared with the antibody alone. Next steps could include clinical testing of capmatinib plus immunotherapies in melanoma, breast cancer and colorectal cancer patients...